目前相关业界同道内普遍认同，既往广泛使用多年的侵袭性淋巴瘤（aggressive lymphoma）的定义范畴．在最新的世界卫生组织（World Health Organization，WHO）2001年分类中，主要包括非霍奇金淋巴瘤（non-Hodgkin’s lymphoma，NHL）...目前相关业界同道内普遍认同，既往广泛使用多年的侵袭性淋巴瘤（aggressive lymphoma）的定义范畴．在最新的世界卫生组织（World Health Organization，WHO）2001年分类中，主要包括非霍奇金淋巴瘤（non-Hodgkin’s lymphoma，NHL）中的弥漫大B细胞淋巴瘤（diffuse large Bcell lymphoma，DLBCL）、套细胞淋巴瘤（mantle cell lymphoma，MCL）、外周T细胞淋巴瘤（peripheral T cell lymphoma，PTCL）及间变大T细胞淋巴瘤（anaplasticlargeTcelllymphoma，ATCL）等。展开更多
1文献来源
Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with highdose chemotherapy and autologous stem-cell support [J]. N Engl J Med, 2004,350： 1287-1295.
1文献来源
Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluated the use of highdose therapy as part of ＂aggressive＂ lymphoma [J]. 4413-4419. primary treatment for J Clin Oncol, 20 （22） ：
Objective To investigate the risk stratification of aggressive B cell lymphoma using the immune microenvironment and clinical factors. Methods A total of 127 patients with aggressive B cell lymphoma between 2014 and 2...Objective To investigate the risk stratification of aggressive B cell lymphoma using the immune microenvironment and clinical factors. Methods A total of 127 patients with aggressive B cell lymphoma between 2014 and 2015 were enrolled in this study. CD4, Foxp3, CDS, CD68, CD163, PD-1, and PD-L1 expression levels were evaluated in paraffin-embedded lymphoma tissues to identify their roles in the risk stratification. Eleven factors were identified for further evaluation using analysis of variance, chi-square, and multinomial logistic regression analysis. Results Significant differences in 11 factors （age, Ann Arbor stage, B symptom, ECOG performance status, infiltrating CD8＋ T cells, PD-L1 expression, absolute blood monocyte count, serum lactate dehydrogenase, serum iron, serum albumin, and serum l^2-microglobulin） were observed among patient groups stratified by at least two risk stratification methods [International Prognostic Index （IPI）, revised IPI, and NCCN-IPI models] （P 〈 0.05）. Concordance rates were high （81.4%-100.0%） when these factors were used for the risk stratification. No difference in the risk stratification results was observed with or without the Ann Arbor stage data. Conclusion We developed a convenient and inexpensive tool for use in risk stratification of aggressive B cell lymphomas, although further studies on the role of immune microenvironmental factors are needed.展开更多
文摘目前相关业界同道内普遍认同，既往广泛使用多年的侵袭性淋巴瘤（aggressive lymphoma）的定义范畴．在最新的世界卫生组织（World Health Organization，WHO）2001年分类中，主要包括非霍奇金淋巴瘤（non-Hodgkin’s lymphoma，NHL）中的弥漫大B细胞淋巴瘤（diffuse large Bcell lymphoma，DLBCL）、套细胞淋巴瘤（mantle cell lymphoma，MCL）、外周T细胞淋巴瘤（peripheral T cell lymphoma，PTCL）及间变大T细胞淋巴瘤（anaplasticlargeTcelllymphoma，ATCL）等。
文摘1文献来源
Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with highdose chemotherapy and autologous stem-cell support [J]. N Engl J Med, 2004,350： 1287-1295.
文摘1文献来源
Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluated the use of highdose therapy as part of ＂aggressive＂ lymphoma [J]. 4413-4419. primary treatment for J Clin Oncol, 20 （22） ：
基金supported by the National Natural Science Foundation of China(81170467 and 81270569)Major Project of PLA Medical S&T Foundation(AWS11C004)Medical Science Research Foundation of Chongqing Health and Family Planning Committee(2015MSXM224)
文摘Objective To investigate the risk stratification of aggressive B cell lymphoma using the immune microenvironment and clinical factors. Methods A total of 127 patients with aggressive B cell lymphoma between 2014 and 2015 were enrolled in this study. CD4, Foxp3, CDS, CD68, CD163, PD-1, and PD-L1 expression levels were evaluated in paraffin-embedded lymphoma tissues to identify their roles in the risk stratification. Eleven factors were identified for further evaluation using analysis of variance, chi-square, and multinomial logistic regression analysis. Results Significant differences in 11 factors （age, Ann Arbor stage, B symptom, ECOG performance status, infiltrating CD8＋ T cells, PD-L1 expression, absolute blood monocyte count, serum lactate dehydrogenase, serum iron, serum albumin, and serum l^2-microglobulin） were observed among patient groups stratified by at least two risk stratification methods [International Prognostic Index （IPI）, revised IPI, and NCCN-IPI models] （P 〈 0.05）. Concordance rates were high （81.4%-100.0%） when these factors were used for the risk stratification. No difference in the risk stratification results was observed with or without the Ann Arbor stage data. Conclusion We developed a convenient and inexpensive tool for use in risk stratification of aggressive B cell lymphomas, although further studies on the role of immune microenvironmental factors are needed.
